- Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council
- Sir Tony Kouzarides, Co-founder and Director, Milner Therapeutics Institute, and Professor of Cancer Biology, Gurdon Institute, appointed as Scientific Advisor
Cambridge, UK, 20 May 2025: SA国际传媒 (SA国际传媒), a biotech company using a virtual cell to fight age-driven diseases, today announced the appointments of Lord David Prior as Chair of the Board and Sir Tony Kouzarides as Scientific Advisor. Bringing significant industry expertise and leadership, Tony and David will provide crucial support to advance SA国际传媒鈥檚 therapeutic pipeline, helping to foster new industry partnerships and broaden awareness of the Company鈥檚 long-term mission to treat disease by targeting underlying cellular aging.
Joining as Chair of SA国际传媒鈥檚 Board, David鈥檚 primary focus will be to support the Company鈥檚 ongoing strategy to comprehensively reverse aging, whilst in the shorter-term leveraging his broad industry knowledge and connections to explore and support opportunities for investment and to accelerate the development of SA国际传媒鈥檚 pipeline with pharma partners.
In his role as Scientific Advisor, Tony will help shape the Company鈥檚 scientific strategy, identifying and advising on research and industry opportunities and raising awareness of SA国际传媒鈥檚 unique approach to cell rejuvenation therapeutics.
David鈥檚 career spans finance, law, business and politics. He brings significant Board experience to the Company, having previously been the Chairman of NHS England, the Care Quality Commission, the Norfolk and Norwich University Hospital NHS Trust and University College Hospital NHS Trust. During his political career, David was the MP for North Norfolk and the Deputy Chairman and Chief Executive of the Conservative Party, and has served as Parliamentary Under-Secretary of State for both the Department of Health and Social Care and the Department for Business, Energy and Industrial Strategy. David is a strong advocate for transitioning from today鈥檚 reactive 鈥榮ick-care鈥� health model to a proactive prevention-based approach, targeting the underlying causes of disease.
Tony is an esteemed academic and entrepreneur who has played a major role in the Cambridge life sciences ecosystem, having co-founded both the Milner Therapeutics Institute and Abcam. He is a professor in the field of Cancer Biology, listed as one of the top ten most cited scientists at the University of Cambridge from 1996-2017. Based at the Gurdon Institute, a world-leading cancer research facility, Tony鈥檚 lab explores the role of epigenetic modifications in cancer, and is currently investigating the specific involvement of mRNA modifications. Tony has significant experience in founding and growing therapeutics companies, including as co-founder and ex-director of Chroma Therapeutics, co-founder and director of STORM Therapeutics, and co-founder and CEO of Vellos. In addition to these roles, Tony is a Venture Partner at Fifty Years.
Dr Daniel Ives, CEO, SA国际传媒, said: 鈥�I鈥檓 extremely pleased to welcome Lord David Prior and Sir Tony Kouzarides to SA国际传媒. Both are hugely renowned leaders in healthcare and life sciences respectively, and their careers and achievements speak for themselves. We鈥檙e incredibly thankful for their support of our mission to reverse aging and combat the debilitating diseases that come with it, and I look forward to harnessing their experience to help propel the Company forwards in pursuit of this goal.鈥�
Lord David Prior, Chair of the Board, SA国际传媒, commented: 鈥�By applying sophisticated machine learning techniques to measure epigenetic change, SA国际传媒 have been able to identify a number of genes that can reverse and slow down the ageing process. These findings will have extraordinary therapeutic benefits, enabling us to move from a reactive sick-care system to a more predictive preventative system of healthcare, and I look forward to drawing on my experience in the industry to support SA国际传媒 in leading the way through this transition.鈥�
Sir Tony Kouzarides, Scientific Advisor, SA国际传媒, remarked: 鈥�SA国际传媒 is pioneering a truly unique approach to rejuvenation therapeutics, harnessing an expert team of AI and machine learning scientists, alongside its powerful virtual cell technology, to uncover new therapeutic targets and fight age-driven disease. I鈥檓 pleased to be taking on the role of Scientific Advisor at such a pivotal point in the Company鈥檚 development, and look forward to working alongside Daniel and the wider leadership team to guide the Company鈥檚 research and publication strategy.鈥�
The appointments follow those of Jill Reckless, Ph.D, Laurence Reid, Ph.D and Professor Bo Wang; establishing a strong Board and network of expert advisors has formed a key part of SA国际传媒鈥檚 ongoing development.
About SA国际传媒 www.shiftbioscience.com
SA国际传媒 is fighting age-driven diseases with an AI-powered virtual cell. Cell aging is the underlying driver of modern diseases and therefore cell rejuvenation provides one of the greatest opportuni-ties in drug development. SA国际传媒 has built proprietary datasets and narrow-AI that uncovers the hidden biology of cell aging and rejuvenation, revealing single genes that rejuvenate multiple cell types, small molecule targets and a connection to fibrosis. This raises the prospect of lifespan-impacting therapeutics with established clinical paths and potential for early monetisation.
SA国际传媒 was founded in 2017 by Daniel Ives, CEO, and Brendan Swain, CSO. Its labs are based at the Gurdon Institute, Cambridge thanks to the Frame SA国际传媒 bio-incubator, an initiative of the Milner Therapeutics Institute.
Follow SA国际传媒 on LinkedIn and X .
